Evaluation of effect of spironolactone on proteinuria in kidney transplant patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230516058205N1

Enrollment

Registered

2023-07-06

Start date

2023-06-22

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proteinuria. Glomerular disorders in diseases classified elsewhere

Interventions

Intervention 1: Intervention group: For the patients in the first group as the intervention group, spironolactone 25 mg tablets will be started half daily and after one month it will be increased to o

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Persons with more than three months after kidney transplantation Proteinuria more than 0.5 gram per day Estimated glomerular filtration rate more than 30 mili liter per minute Consent to participate in study

Exclusion criteria

Exclusion criteria: Serum potassium more than 5.5 Gynechomastia Transplant dysfunction(eGFR<30) Spironolactone usage for heart and liver failure sensitivity to spironolactone

Design outcomes

Primary

Measure	Time frame
Urine protein. Timepoint: Monthly. Method of measurement: 24 hours urine sample.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbdolamir Atapour

Esfahan University of Medical Sciences

pejmanpoorshabanan@hotmail.com+98 31 3641 1396

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026